Member Info for Laura2022

I'm also down in monetary terms but optimistic that finally PYC are in right place at right time with right product (s)and right CEO

I have added over the last 9mths a bit at a time where I can

The best research comes from Debull and others while a great summary of reasons to be optimistic comes from Kinghomer and others

I will post King H summaries

My view is £1.4mln cap for highest ever contracts won (£900k) amd already booked £500k for month 1 of next 12mths + potential for significant scale up of contracts and dosing tool makes PYC so undervalued

These are my personal thoughts

Thankyou

You'd think that with these long term large clients where we've proven our tech/ knowledge..that larger maybe recurring contracts (and/or royalty agreement) should be considered by PS ?

Apologies ignore me

It's in relation to Iano posting

Morning Debull

Was thus in relation to a specific Bicycle Q ?

X 6 the market valuation

Not surprised lenders are getting cold feet

GB

not sure if you're still in the A.I bio tech but big news possibly from AZN due

Thankyou iano

Was that today?

Nice big buy just now

Nah

Reckon it will still be covid

Morning Siennaj

Yeah I meant 50k-100k +

My appog9es

Kilkenny

Alot of re rate (from lowly £1.4mln cap) and news due

Excellent summary from KingH

This is severely undervalued at current MC.

Even at 2p (4 Million MC) its still a steal....lots of news to come to build from here.

* Highest Level of Revenue going into financial year £600k (We are 2 months into it)

* Dosemerx update & Collab

* NHS Prostate Cancer Trial ongoing - update due

* Beyond Blood Trial ongoing - update due (i would suggest people look at the shareholders on this one) Companies House

* Bicycle Therapeutics Update due - to be announced in September

* New Revenue Arm launched

* New Recruit has moved from AstraZeneca

* VAL 201 (Up to £6mil) if that ever ever ever happens who knows....

Still NT

All I know it was NT to buy at 0 7p but almost 0.693 to sell

Narrowest I've seen here for many months

At AstraZeneca we harness data and technology to maximise time for the discovery and delivery of potential new medicines. Data science and artificial intelligence (AI) are embedded across our R&D to enable our scientists to push the boundaries of science to deliver life-changing medicines.

Data science and AI are transforming R&D, helping us turn science into medicine more quickly and with a higher probability of success. We are applying AI throughout the discovery and development process, from target identification to clinical trials, to uncover new insights to guide our drug discovery and developmen

Announce that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic area

I suppose this could cover a multitude of clients but wording "forefront " suggests a large/well known one ?

Morning Debull

It's been strange all week so far, but all I know is that after about 4.15

was impossible to buy at all after a flurry of buys

Thanks Ralph

This was the original initial contract August 2022? So I assume we may get /have got further work with them judging by the tweet

 announce that it has been awarded a contract by new client, the Servier Group (“Servier”), an international pharmaceutical company headquartered in France.  Cancer is one of Servier’s priority therapy areas and it has a particular focus on immunotherapies and monoclonal antibodies for difficult to treat diseases with high unmet medical needs.

Physiomics PLC

@Physiomics

Huge congratulations to our client

@ServierPharma

on the #FDA approval of VORANIGO®! This is an incredible milestone in #precisionmedicine, especially for those facing the tough battle against brain tumours.

For the last 30mins

Total voting rights

Following Admission, the total issued share capital of the Company will be 3,914,344,012 Ordinary Shares. Accordingly, the figure of 3,914,344,012 is to be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparen

I have looked back and it's looks like x 3 the new shares have been traded at least so don't think there is much if any to shift

It will say it on the bottom of last weeks RNS 20teen